| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000028955198 |
| Molecular Weight (Da) | 442 |
| SMILES | CC1CCN(C(=O)c2ccc3c(c2)c2c(n3Cc3ccccc3)CN(C3CCCC3)C2)CC1 |
| Molecular Formula | C29N3O1 |
| Action | Agonist |
| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000028955198 |
| Molecular Weight (Da) | 442 |
| SMILES | CC1CCN(C(=O)c2ccc3c(c2)c2c(n3Cc3ccccc3)CN(C3CCCC3)C2)CC1 |
| Molecular Formula | C29N3O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000028955198 |
| Molar Refractivity | 132.736 |
| HBA | 1 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 33 |
| LogP | 5.713 |
| Activity (Ki) in nM | 107.152 |
| Polar Surface Area (PSA) | 28.48 |
| Pharmacokinetic Properties | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000028955198 |
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | - |
| Oatp2b1 inhibitor | - |
| Oatp1b1 inhibitor | + |
| Oatp1b3 inhibitor | + |
| Mate1 inhibitor | - |
| Oct2 inhibitor | + |
| Bsep inhibitor | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 0.94406235 |
| Pharmacokinetic Properties | |
|---|---|
| Number of aromatic heavy atoms | 15 |
| Fraction csp3 | 0.48 |
| Ilogp | 4.45 |
| Xlogp3 | 5.05 |
| Wlogp | 4.75 |
| Mlogp | 4.32 |
| Silicos-it log p | 4.96 |
| Consensus log p | 4.71 |
| Esol log s | -5.77 |
| Esol solubility (mg/ml) | 0.000757 |
| Esol solubility (mol/l) | 0.00000171 |
| Esol class | Moderately |
| Ali log s | -5.39 |
| Ali solubility (mg/ml) | 0.0018 |
| Ali solubility (mol/l) | 0.00000408 |
| Ali class | Moderately |
| Silicos-it logsw | -7.14 |
| Silicos-it solubility (mg/ml) | 0.0000321 |
| Silicos-it solubility (mol/l) | 7.28E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.41 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 1 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 4.19 |
| Pharmacokinetic Properties | |
|---|---|
| Logs | -4.698 |
| Logd | 4.487 |
| Logp | 5.26 |
| F (20%) | 0.013 |
| F (30%) | 0.007 |
| Mdck | 1.20E-05 |
| Ppb | 0.9548 |
| Vdss | 2.219 |
| Fu | 0.0159 |
| Cyp1a2-inh | 0.122 |
| Cyp1a2-sub | 0.778 |
| Cyp2c19-inh | 0.84 |
| Cyp2c19-sub | 0.071 |
| Cl | 5.466 |
| T12 | 0.068 |
| H-ht | 0.981 |
| Dili | 0.884 |
| Roa | 0.75 |
| Fdamdd | 0.905 |
| Skinsen | 0.274 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.571 |
| Bcf | 1.918 |
| Igc50 | 5.024 |
| Lc50 | 5.471 |
| Lc50dm | 5 |
| Nr-ar | 0.381 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.55 |
| Nr-aromatase | 0.548 |
| Nr-er | 0.186 |
| Nr-er-lbd | 0.371 |
| Nr-ppar-gamma | 0.017 |
| Sr-are | 0.445 |
| Sr-atad5 | 0.007 |
| Sr-hse | 0.383 |
| Sr-mmp | 0.315 |
| Sr-p53 | 0.26 |
| Vol | 479.49 |
| Dense | 0.92 |
| Flex | 0.156 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 2 |
| Qed | 0.51 |
| Synth | 2.467 |
| Fsp3 | 0.483 |
| Mce-18 | 76.744 |
| Natural product-likeness | -0.922 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |